MRVI

Maravai LifeSciences Holdings, Inc. [MRVI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

MRVI Stock Summary

Top 10 Correlated ETFs

MRVI


Top 10 Correlated Stocks

MRVI


In the News

08:15 30 Nov 2023 MRVI

Maravai LifeSciences Announces November 2023 Investor Conference Schedule

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of November.

03:54 30 Nov 2023 MRVI

Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2023 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Deb Hart - Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Executive Vice President and Chief Commercial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tom Peterson - Baird Matt Larew - William Blair Michael Ryskin - Bank of America Conor McNamara - RBC Capital Markets Dan Arias - Stifel Justin Bowers - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by. My name is Tammy and I will be your conference operator today.

08:15 30 Nov 2023 MRVI

Maravai LifeSciences To Host Earnings Conference Call on Tuesday, November 7, 2023

SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2023 financial and operating results after the market closes on Tuesday, November 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

04:36 30 Nov 2023 MRVI

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2023 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2023 Earnings Call Transcript August 7, 2023 5:00 PM ET Company Participants Debra Hart - Head of IR Carl Hull - Executive Chairman of the Board Trey Martin - CEO Kevin Herde - CFO Becky Buzzeo - CCO Drew Burch - EVP, and GM Nucleic Acid Production Conference Call Participants Matt Sykes - Goldman Sachs Conor McNamara - RBC Capital Markets Dan Leonard - Credit Suisse Catherine Schulte - Baird Justin Bowers - Deutsche Bank Tejas Savant - Morgan Stanley Madeline Mollman - William Blair John Sourbeer - UBS Operator Thank you for standing by. I would like to welcome everyone to the Quarter Two 2023 Maravai LifeSciences' Earnings Conference Call.

04:05 30 Nov 2023 MRVI

Maravai LifeSciences To Host Earnings Conference Call on Monday, August 7, 2023

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2023 financial and operating results after the market closes on Monday, August 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

07:52 30 Nov 2023 MRVI

Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2023 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Deb Hart - Head of Investor Relations Carl Hull - Chairman of the Board and Interim CEO Kevin Herde - Chief Financial Officer Becky Buzzeo - Chief Commercial Officer Trey Martin - President Biologics Safety Testing Drew Burch - EVP, Nucleic Acid Production Conference Call Participants Conor McNamara - RBC Capital Markets Catherine Schulte - Robert W. Baird Matthew Sykes - Goldman Sachs Daniel Leonard - Credit Suisse Daniel Arias - Stifel John Sourbeer - UBS Tejas Savant - Morgan Stanley Operator Good afternoon.

07:02 30 Nov 2023 MRVI

Maravai LifeSciences Holdings, Inc. (MRVI) Lags Q1 Earnings and Revenue Estimates

Maravai LifeSciences Holdings, Inc. (MRVI) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.54 per share a year ago.

04:15 30 Nov 2023 MRVI

Maravai LifeSciences To Host Earnings Conference Call on Monday, May 8, 2023

SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2023 financial and operating results after the market closes on Monday, May 8, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

08:45 30 Nov 2023 MRVI

2 Top Biotech Stocks to Buy In March and Hold Forever

Long-term investments in biotech tend to be hard to come by. Moderna's gargantuan pipeline means that it has a very long growth runway ahead.

08:00 30 Nov 2023 MRVI

Maravai LifeSciences Announces March 2023 Investor Conference Schedule

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of March.

MRVI Financial details

Company Rating
Strong Buy
Market Cap
1.34B
Income
73.08M
Revenue
419.52M
Book val./share
3.94
Cash/share
4.39
Dividend
-
Dividend %
-
Employees
670
Optionable
No
Shortable
Yes
Earnings
20 Feb 2024
P/E
9.24
Forward P/E
64.69
PEG
-1.07
P/S
3.07
P/B
1.3
P/C
1.18
P/FCF
4.8
Quick Ratio
16.7
Current Ratio
8.96
Debt / Equity
1.07
LT Debt / Equity
0.62
-
-
EPS (TTM)
0.55
EPS next Y
0.08
EPS next Q
0.02
EPS this Y
-8.8%
EPS next Y
-85.49%
EPS next 5Y
-49.53%
EPS last 5Y
NAN%
Revenue last 5Y
48.12%
Revenue Q/Q
-2.97%
EPS Q/Q
-1.21%
-
-
-
-
SMA20
-28.57%
SMA50
-50%
SMA100
-58.33%
Inst Own
66.8%
Inst Trans
0.71%
ROA
3%
ROE
14%
ROC
0.04%
Gross Margin
60%
Oper. Margin
19%
Profit Margin
17%
Payout
-
Shs Outstand
251.28M
Shs Float
103.02M
-
-
-
-
Target Price
23.5
52W Range
4.52-16.9
52W High
-67.66%
52W Low
+29.38%
RSI
36
Rel Volume
0.7
Avg Volume
2.66M
Volume
1.87M
Perf Week
4.97%
Perf Month
-28.03%
Perf Quarter
-60.28%
Perf Half Y
-60.22%
-
-
-
-
Beta
-0.112
-
-
Volatility
0.11%, 0.85%
Prev Close
1.07%
Price
5.175
Change
1.67%

MRVI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.391.6127.456.966.71
Net income per share
-0.2-0.068.64.093.73
Operating cash flow per share
00.2714.73.214.07
Free cash flow per share
-0.040.0812.253.083.94
Cash per share
0.250.2822.824.84.81
Book value per share
1.621.598.552.754.14
Tangible book value per share
-3.31-3.12-23.882.43.08
Share holders equity per share
1.621.598.552.754.14
Interest debt per share
4.134.7260.044.924.6
Market cap
2.66B2.66B290.35M4.81B1.88B
Enterprise value
2.97B3.02B644.94M4.79B1.84B
P/E ratio
-149.77-510.63.2610.253.84
Price to sales ratio
21.4518.551.026.022.13
POCF ratio
-14.28K110.121.9113.053.51
PFCF ratio
-699.4381.172.2913.63.63
P/B Ratio
18.3918.783.2815.243.45
PTB ratio
18.3918.783.2815.243.45
EV to sales
24.0121.112.2762.08
Enterprise value over EBITDA
74.762.286.98.823.23
EV to operating cash flow
-15.99K125.284.24133.42
EV to free cash flow
-783.16433.635.0913.553.54
Earnings yield
-0.0100.310.10.26
Free cash flow yield
000.440.070.28
Debt to equity
2.352.766.671.691.07
Debt to assets
0.630.680.460.280.26
Net debt to EBITDA
7.997.533.8-0.03-0.08
Current ratio
1.52.052.547.897.7
Interest coverage
0.60.82.218.3328.13
Income quality
0.01-4.641.930.791.09
Dividend Yield
0.0202.100
Payout ratio
-2.9406.8500
Sales general and administrative to revenue
0.330000
Research and developement to revenue
0.040.030.030.020.02
Intangibles to total assets
0.820.730.320.140.22
Capex to operating cash flow
19.41-0.71-0.17-0.04-0.03
Capex to revenue
-0.03-0.12-0.09-0.02-0.02
Capex to depreciation
-0.16-0.71-0.98-0.6-0.45
Stock based compensation to revenue
0.020.010.090.010.02
Graham number
2.71.4540.6715.918.65
ROIC
0.030.040.090.570.43
Return on tangible assets
-0.18-0.030.10.280.28
Graham Net
-3.94-4.36-79.69-6.17-4.66
Working capital
17.88M30.99M200.82M646.26M737.76M
Tangible asset value
-294.39M-277.5M-247.19M275.02M404.91M
Net current asset value
-337.86M-372.62M-784.35M-632.88M-529.17M
Invested capital
2.352.766.671.691.07
Average receivables
017.01M34.52M84.27M132.16M
Average payables
05.54M7.82M8.16M7.07M
Average inventory
014.26M23.75M42.43M47.35M
Days sales outstanding
47.1345.9865.5553.6760.69
Days payables outstanding
21.6540.8337.4421.1712.94
Days of inventory on hand
85.9477.54152.61133.8893.22
Receivables turnover
7.747.945.576.86.01
Payables turnover
16.868.949.7517.2428.2
Inventory turnover
4.254.712.392.733.92
ROE
-0.12-0.041.011.490.9
Capex per share
-0.04-0.19-2.45-0.13-0.13

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.451.560.60.520.51
Net income per share
0.760.66-0.01-0.05-0.05
Operating cash flow per share
0.840.750.650.150
Free cash flow per share
0.790.710.59-0.040
Cash per share
4.694.84.774.44.39
Book value per share
3.834.143.963.953.94
Tangible book value per share
2.553.082.522.552.56
Share holders equity per share
3.834.143.963.953.94
Interest debt per share
4.084.524.774.734.31
Market cap
3.36B1.88B1.85B1.64B1.32B
Enterprise value
3.27B1.84B1.83B1.68B1.3B
P/E ratio
8.425.39-342.3-62.65-51.04
Price to sales ratio
17.569.223.3623.7819.73
POCF ratio
30.5118.9621.6985.390
PFCF ratio
32.4220.2323.91-279.470
P/B Ratio
6.673.453.543.152.54
PTB ratio
6.673.453.543.152.54
EV to sales
17.128.9723.224.3219.4
Enterprise value over EBITDA
28.0116.33209.66-191.36-234.43
EV to operating cash flow
29.7618.4921.5587.330
EV to free cash flow
31.6119.7223.75-285.790
Earnings yield
0.030.05000
Free cash flow yield
0.030.050.0400
Debt to equity
1.061.071.181.191.07
Debt to assets
0.240.260.270.270.25
Net debt to EBITDA
-0.71-0.42-1.37-4.233.97
Current ratio
7.227.76.139.338.96
Interest coverage
37.2810.73-0.18-1.65-1.32
Income quality
1.11.14-63.11-1.610
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.030.020.050.060.07
Intangibles to total assets
0.230.220.250.250.24
Capex to operating cash flow
-0.06-0.06-0.09-1.310
Capex to revenue
-0.03-0.03-0.1-0.360
Capex to depreciation
-0.65-0.62-0.72-2.120
Stock based compensation to revenue
0.020.030.080.130
Graham number
8.087.870.952.12.08
ROIC
0.10.080-0.01-0.01
Return on tangible assets
0.060.05000
Graham Net
-5.01-4.66-5.44-5.51-1.71
Working capital
719.87M737.76M640.62M624.39M622.61M
Tangible asset value
335.24M404.91M332.49M336.45M338.4M
Net current asset value
-571.7M-529.17M-649.24M-667.49M-674.41M
Invested capital
1.061.071.181.191.07
Average receivables
130.58M139.52M101.85M53.05M388.41M
Average payables
16.36M7.73M5.39M5.72M8.04M
Average inventory
61.27M52.79M48.99M51.11M48.27M
Days sales outstanding
62.2264.5564.7964.28979.35
Days payables outstanding
22.310.1312.7913.8523.12
Days of inventory on hand
147.1672.93146.5198.59120.56
Receivables turnover
1.451.391.391.40.09
Payables turnover
4.048.897.046.53.89
Inventory turnover
0.611.230.610.910.75
ROE
0.20.160-0.01-0.01
Capex per share
-0.05-0.05-0.06-0.190

MRVI Frequently Asked Questions

What is Maravai LifeSciences Holdings, Inc. stock symbol ?

Maravai LifeSciences Holdings, Inc. is a US stock , located in San diego of Ca and trading under the symbol MRVI

Is Maravai LifeSciences Holdings, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $23.5. The lowest prediction is $22 and the highest is $25

What is MRVI stock prediction ?

What is Maravai LifeSciences Holdings, Inc. stock quote today ?

Maravai LifeSciences Holdings, Inc. stock price is $5.175 today.

Is Maravai LifeSciences Holdings, Inc. stock public?

Yes, Maravai LifeSciences Holdings, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap